[go: up one dir, main page]

LT2744330T - Pakeisti (e)-n`-(1-feniletilideno) benzohidrazido analogai, kaip histonų demetilazės inhibitoriai - Google Patents

Pakeisti (e)-n`-(1-feniletilideno) benzohidrazido analogai, kaip histonų demetilazės inhibitoriai

Info

Publication number
LT2744330T
LT2744330T LTEP12823540.5T LT12823540T LT2744330T LT 2744330 T LT2744330 T LT 2744330T LT 12823540 T LT12823540 T LT 12823540T LT 2744330 T LT2744330 T LT 2744330T
Authority
LT
Lithuania
Prior art keywords
demetylase
phenylethylene
histone
inhibitors
modified
Prior art date
Application number
LTEP12823540.5T
Other languages
English (en)
Inventor
Hariprasad Vankayalapati
Venkataswamy SORNA
Steve Warner
David Bearss
Sunil Sharma
Bret STEPHENS
Original Assignee
University Of Utah Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Utah Research Foundation filed Critical University Of Utah Research Foundation
Publication of LT2744330T publication Critical patent/LT2744330T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
    • C07C311/46—Y being a hydrogen or a carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
LTEP12823540.5T 2011-08-15 2012-08-15 Pakeisti (e)-n`-(1-feniletilideno) benzohidrazido analogai, kaip histonų demetilazės inhibitoriai LT2744330T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161523801P 2011-08-15 2011-08-15
PCT/US2012/050948 WO2013025805A1 (en) 2011-08-15 2012-08-15 Substituted (e)-n'-(1-phenylethylidene) benzohydrazide analogs as histone demethylase inhiitors

Publications (1)

Publication Number Publication Date
LT2744330T true LT2744330T (lt) 2020-10-26

Family

ID=47715455

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP12823540.5T LT2744330T (lt) 2011-08-15 2012-08-15 Pakeisti (e)-n`-(1-feniletilideno) benzohidrazido analogai, kaip histonų demetilazės inhibitoriai

Country Status (26)

Country Link
US (2) US8987335B2 (lt)
EP (1) EP2744330B1 (lt)
JP (1) JP6122006B2 (lt)
KR (1) KR101983537B1 (lt)
CN (1) CN103929960B (lt)
AU (1) AU2012296639B2 (lt)
BR (1) BR112014003382B1 (lt)
CA (1) CA2843609C (lt)
CY (1) CY1123345T1 (lt)
DK (1) DK2744330T3 (lt)
EA (1) EA026389B1 (lt)
ES (1) ES2821548T3 (lt)
HK (1) HK1200052A1 (lt)
HR (1) HRP20201433T1 (lt)
HU (1) HUE050962T2 (lt)
IL (1) IL230728A (lt)
IN (1) IN2014CN00961A (lt)
LT (1) LT2744330T (lt)
MX (1) MX356486B (lt)
PL (1) PL2744330T3 (lt)
PT (1) PT2744330T (lt)
SG (1) SG2014009609A (lt)
SI (1) SI2744330T1 (lt)
SM (1) SMT202000551T1 (lt)
WO (1) WO2013025805A1 (lt)
ZA (1) ZA201400881B (lt)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9266838B2 (en) 2011-08-15 2016-02-23 University Of Utah Research Foundation Substituted (E)-N′-(1-phenylethylidene)benzohydrazide analogs as histone demethylase inhibitors
PT2903968T (pt) 2012-10-02 2017-03-13 Gilead Sciences Inc Inibidores de desmetilases de histonas
EP2961736B1 (en) 2013-02-27 2018-04-11 Gilead Sciences, Inc. Inhibitors of histone demethylases
EP2968282B1 (en) * 2013-03-12 2018-05-09 Celgene Quanticel Research, Inc. Histone dementhylase inhibitors
SG11201510376QA (en) * 2013-06-19 2016-01-28 Univ Utah Res Found Substituted (e)-n'-(1-phenylethylidene) benzohydrazide analogs as histone demethylase inhibitors
MY183499A (en) 2014-02-13 2021-02-22 Incyte Corp Cyclopropylamines as lsd1 inhibitors
CR20160395A (es) 2014-02-13 2016-12-20 Incyte Corp Ciclopropilaminas como inhibidores de lsd1
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
ES2672797T3 (es) 2014-02-13 2018-06-18 Incyte Corporation Ciclopropilaminas como inhibidores de LSD1
US10807944B2 (en) 2014-04-04 2020-10-20 University Of Florida Research Foundation, Inc. HDAC inhibitor compounds and methods of treatment
US20170144965A1 (en) * 2014-06-05 2017-05-25 The University Of Kansas Marmelin analogs and methods of use in cancer treatment
US9695168B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted imidazo[1,5-α]pyridines and imidazo[1,5-α]pyrazines as LSD1 inhibitors
US9695167B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors
US9695180B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors
US9758523B2 (en) 2014-07-10 2017-09-12 Incyte Corporation Triazolopyridines and triazolopyrazines as LSD1 inhibitors
EA201790154A1 (ru) 2014-08-27 2017-08-31 Джилид Сайэнс, Инк. Соединения и способы для ингибирования гистоновых деметилаз
EP2993175A1 (en) 2014-09-05 2016-03-09 IEO - Istituto Europeo di Oncologia Srl Thienopyrroles as histone demethylase inhibitors
CN106146361A (zh) * 2015-03-16 2016-11-23 四川大学 茚-1-亚基磺酰基苯甲酰肼衍生物及其制备方法和用途
MA51438A (fr) 2015-04-03 2021-04-14 Incyte Corp Composés hétérocycliques utilisés en tant qu'inhibiteurs de lsd1
SG10201911989SA (en) 2015-06-12 2020-02-27 Oryzon Genomics Sa Biomarkers associated with lsd1 inhibitors and uses thereof
WO2017013061A1 (en) 2015-07-17 2017-01-26 Oryzon Genomics, S.A. Biomarkers associated with lsd1 inhibitors and uses thereof
SG10202001219UA (en) 2015-08-12 2020-03-30 Incyte Corp Salts of an lsd1 inhibitor
CN109195593A (zh) 2016-03-15 2019-01-11 奥莱松基因组股份有限公司 用于治疗实体瘤的lsd1抑制剂的组合
ES3042059T3 (en) 2016-03-16 2025-11-18 Oryzon Genomics Sa Methods to determine kdm1a target engagement and chemoprobes useful therefor
CR20180553A (es) 2016-04-22 2019-02-01 Incyte Corp Formulaciones de un inhibidor de lsd1
EP3246330A1 (en) 2016-05-18 2017-11-22 Istituto Europeo di Oncologia S.r.l. Imidazoles as histone demethylase inhibitors
EP3487490A4 (en) * 2016-07-19 2020-01-15 The General Hospital Corporation TARGETING COMPOUNDS OF CANCER STEM CELLS
WO2018083138A1 (en) 2016-11-03 2018-05-11 Oryzon Genomics, S.A. Pharmacodynamic biomarkers for personalized cancer care using epigenetic modifying agents
US20190256930A1 (en) 2016-11-03 2019-08-22 Oryzon Genomics, S.A. Biomarkers for determining responsiveness to lsd1 inhibitors
US20200069677A1 (en) 2016-12-09 2020-03-05 Constellation Pharmaceuticals, Inc. Markers for personalized cancer treatment with lsd1 inhibitors
CN106831489B (zh) * 2017-03-23 2018-04-17 郑州大学 苯环丙胺酰腙类化合物、制备方法及其应用
DK3661510T3 (da) 2017-08-03 2025-01-02 Oryzon Genomics Sa Fremgangsmåder til behandling af adfærdsændringer
AU2018316542B2 (en) 2017-08-18 2023-02-16 Istituto Europeo Di Oncologia (Ieo) S.R.L. Indole derivatives as histone demethylase inhibitors
WO2019068326A1 (en) 2017-10-05 2019-04-11 Université D'aix-Marseille INHIBITORS OF LSD1 FOR THE TREATMENT AND PREVENTION OF CARDIOMYOPATHIES
SMT202200134T1 (it) 2018-03-08 2022-05-12 Incyte Corp Composti di amminopirazindiolo come inibitori di pi3k-y
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors
WO2020047198A1 (en) 2018-08-31 2020-03-05 Incyte Corporation Salts of an lsd1 inhibitor and processes for preparing the same
CN109793742A (zh) * 2019-03-04 2019-05-24 四川大学华西医院 一种药物化合物应用
CN109758442B (zh) * 2019-03-20 2021-08-17 武汉大学 二芳基酰肼类化合物在制备抗流感病毒药物中的应用
CN121370879A (zh) 2019-03-20 2026-01-23 奥莱松基因组股份有限公司 治疗边缘型人格障碍的方法
EP3941465B1 (en) 2019-03-20 2025-09-17 Oryzon Genomics, S.A. Methods of treating attention deficit hyperactivity disorder using kdm1a inhibitors such as the compound vafidemstat
WO2021004610A1 (en) 2019-07-05 2021-01-14 Oryzon Genomics, S.A. Biomarkers and methods for personalized treatment of small cell lung cancer using kdm1a inhibitors
WO2022020804A1 (en) * 2020-07-24 2022-01-27 Salarius Pharmaceuticals Llc Methods of inhibiting lysine-specific demethylase 1 (lsd-1)
EP3964204A1 (en) 2020-09-08 2022-03-09 Université d'Aix-Marseille Lsd1 inhibitors for use in the treatment and prevention of fibrosis of tissues
BR112023020554A2 (pt) 2021-04-08 2023-12-05 Oryzon Genomics Sa Combinações de inibidores de lsd1 para o tratamento de cânceres mieloides
JP2025516647A (ja) 2022-05-09 2025-05-30 オリゾン・ゲノミクス・ソシエダッド・アノニマ Ｌｓｄ１阻害薬を用いる悪性末梢神経鞘腫（ｍｐｎｓｔ）の治療法
CN119497613A (zh) 2022-05-09 2025-02-21 奥莱松基因组股份有限公司 使用lsd1抑制剂治疗nf1-突变肿瘤的方法
CN116077661B (zh) * 2022-08-22 2024-09-27 沈阳药科大学 Kdm1a抑制剂在制备治疗dnmt3a基因缺失癌症的药物中的用途
CN120529900A (zh) 2022-11-24 2025-08-22 奥莱松基因组股份有限公司 用于治疗癌症的LSD1抑制剂和Menin抑制剂的组合

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004525118A (ja) * 2001-01-22 2004-08-19 アルパイダ　アーゲー 新規ヒドラゾン類
JP2002302472A (ja) * 2001-01-31 2002-10-18 Meiji Seika Kaisha Ltd メイラード反応阻害剤
US20070042997A1 (en) 2003-07-16 2007-02-22 Akiko Itai Medicament for treatment of dermal pigmentation
WO2006136008A1 (en) 2005-05-24 2006-12-28 University Health Network Salicylic acid hydrazones as inhibitors of the erk mapkinase pathway and for the treatment of cancer
TW200800145A (en) * 2005-08-26 2008-01-01 Dekk Tec Inc Hydrazone agents to treat cutaneous lesions
KR20080070848A (ko) 2005-11-03 2008-07-31 레드포인트 바이오 코포레이션 히드라존 유도체 및 이의 용도
US8338464B2 (en) 2006-11-30 2012-12-25 Albert Einstein College Of Medicine Of Yeshiva University Small molecule inhibitors of BCL6
WO2008097504A2 (en) 2007-02-02 2008-08-14 Redpoint Bio Corporation Use of a trpm5 inhibitor to regulate insulin and glp-1 release
WO2008121877A2 (en) * 2007-04-02 2008-10-09 Institute For Oneworld Health Cftr inhibitor compounds and uses thereof
EP2195029A2 (en) * 2007-08-24 2010-06-16 Oryzon Genomics SA Treatment and prevention of neurodegenerative diseases
AR070898A1 (es) * 2008-03-18 2010-05-12 Solvay Pharm Bv Derivados de arilsulfonil pirazolin carboxamidina como antagonistas de 5-ht6
US20100048638A1 (en) 2008-07-01 2010-02-25 Zacharon Pharmaceuticals, Inc. Heparan sulfate inhibitors
EP2376437A2 (en) * 2009-01-14 2011-10-19 Dow AgroSciences LLC Fungicidal compositions including hydrazone derivatives and copper
US20110189306A1 (en) * 2010-01-13 2011-08-04 Norbert Kartner COMPOUNDS, COMPOSITIONS AND TREATMENTS FOR V-ATPase RELATED DISEASES

Also Published As

Publication number Publication date
IL230728A0 (en) 2014-03-31
PL2744330T3 (pl) 2020-12-14
JP6122006B2 (ja) 2017-04-26
MX356486B (es) 2018-05-30
JP2014527531A (ja) 2014-10-16
AU2012296639B2 (en) 2016-06-09
IL230728A (en) 2017-05-29
KR20140077887A (ko) 2014-06-24
US20150150864A1 (en) 2015-06-04
AU2012296639A1 (en) 2014-03-06
ES2821548T3 (es) 2021-04-26
BR112014003382B1 (pt) 2022-03-15
CA2843609A1 (en) 2013-02-21
US9555024B2 (en) 2017-01-31
PT2744330T (pt) 2020-10-01
IN2014CN00961A (lt) 2015-04-10
HRP20201433T1 (hr) 2020-12-11
US8987335B2 (en) 2015-03-24
BR112014003382A2 (pt) 2017-11-21
EA026389B1 (ru) 2017-04-28
EP2744330A1 (en) 2014-06-25
NZ621078A (en) 2015-10-30
CY1123345T1 (el) 2022-03-24
CA2843609C (en) 2020-12-08
CN103929960B (zh) 2016-08-17
SMT202000551T1 (it) 2020-11-10
WO2013025805A1 (en) 2013-02-21
KR101983537B1 (ko) 2019-05-29
HK1200052A1 (en) 2015-07-31
HUE050962T2 (hu) 2021-01-28
ZA201400881B (en) 2015-07-29
EP2744330A4 (en) 2015-03-25
SI2744330T1 (sl) 2020-11-30
SG2014009609A (en) 2014-05-29
EA201490453A1 (ru) 2014-09-30
MX2014001842A (es) 2014-07-24
EP2744330B1 (en) 2020-07-15
CN103929960A (zh) 2014-07-16
US20140094445A1 (en) 2014-04-03
DK2744330T3 (da) 2020-09-07

Similar Documents

Publication Publication Date Title
LT2744330T (lt) Pakeisti (e)-n`-(1-feniletilideno) benzohidrazido analogai, kaip histonų demetilazės inhibitoriai
FIC20230004I1 (fi) Melfalaaniflufenamidihydrokloridi
IL265152A (en) Sample array coding for low-delay
IL243200A0 (en) Converted analogs of (e)-n'-(1-phenylethylidene)benzohydrazide as histone demethylase inhibitors
DK2693881T3 (da) Substituerede n-phenylpyrimidin-2-amin-analoger som inhibitorer af axl-kinase
DK3673906T3 (da) Glycosylceramidsyntase-hæmmere
HUE037312T2 (hu) Hiszton demetiláz inhibitorok
DK3689878T3 (da) 4-imidazopyridazin-1-yl-benzamider og 4-imidazotriazin-1-yl-benzamider som btk-inhibitorer
EP3159459C0 (en) DATA CENTER
DK2920149T3 (da) 3-aminocycloalkyl-forbindelser som ror-gamma-t-inhibitorer og anvendelser deraf
DK3269802T3 (da) Forbindelser til forbedret virustransduktion
EG26841A (en) Oxidation system with sidedraw secondary reactor
LT3702351T (lt) Kompozicijos, apimančios mek inhibitorių
DK2678329T3 (da) Triazolopyridinforbindelser som pim-kinase-hæmmere
CO6900146A2 (es) Imidazopiridazinas sustituidas con amino
EP2669270A4 (en) ANNELLED CONNECTION
PT2687518T (pt) Composto heterocíclico saturado contendo azoto
BR112013031218A2 (pt) protetores solares
FR2985007B1 (fr) Regenerateur.
EP2723489A4 (en) DISTRIBUTOR DE GAZ D'UN DISPOSITIQUE D'OXYDATION DE NH3
BR112013031107A2 (pt) protetores solares
EP2684039A4 (en) INHIBITORS OF PEPTIDE DEFORMYLASE
FR2977660B1 (fr) Regenerateur
EP2848622A4 (en) Aromatic ring compound
EP2848621A4 (en) AROMATIC RING CONNECTION